Simulations Plus
SLPSimulations Plus is a global provider of modeling and simulation software and consulting services for the biopharmaceutical, agrochemical, and cosmetics industries.
Earnings
Next report
Oct 29, 2026 (in 3 months)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Simulations Plus is a global provider of modeling and simulation software and consulting services for the biopharmaceutical, agrochemical, and cosmetics industries. The company offers a comprehensive suite of solutions that utilize artificial intelligence and machine learning to accelerate drug discovery, optimize clinical trial design, and support regulatory submissions. Its core value proposition lies in reducing the time and cost of research and development by predicting molecular properties and simulating clinical outcomes.
A premier provider and global leader in model-informed drug development (MIDD) and biosimulation software.
FAQ
- What is Simulations Plus's market cap?
- Simulations Plus (SLP) has a market capitalization of $370.1M and trades on NASDAQ.
- What is Simulations Plus's revenue and profitability?
- Simulations Plus generated $82.1M in trailing twelve-month revenue with net income of $8.1M, representing a net margin of 9.9%. Gross margin stands at 63.4%, with free cash flow of $24.5M. These figures are based on the Q2 2026 filing.
- Who are Simulations Plus's competitors?
- Simulations Plus's key competitors include Certara, Schrodinger, Shuttle Pharmaceuticals Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Simulations Plus have?
- Simulations Plus's subsidiaries include Pro-ficiency, DILIsym Services, Lixoft.
- Where is Simulations Plus headquartered?
- Simulations Plus is headquartered in United States of America and employs approximately 197 people. It has been publicly traded since 1997.
